Bioavailability measurements of methazolamide in plasma, red blood cells and whole blood: Implications for bioequivalence studies

International Journal of Pharmaceutics

Volumn 138, Issue 2, 1996, Pages 207-213

  Pradhan, Sikta ^a   Wu, Agnes T ^a   Lesko, Lawrence J ^a   Chen, Mei Ling ^a   Williams, Roger L ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Bioequivalence study; Distribution; Dose proportionality; Methazolamide; Parameters; Pharmacokinetic; Plasma; Red blood cell; Whore blood

Indexed keywords

METHAZOLAMIDE;

ADULT; AGED; ARTICLE; BIOAVAILABILITY; BIOEQUIVALENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ERYTHROCYTE LEVEL; FEMALE; GLAUCOMA; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL;

EID: 0029745392     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-5173(96)04536-X     Document Type: Article

References (13)

1. Bayne, W.F., Tao, F.T., Rogers, G., Chu, L.C. and Theeuwes, F., Time and disposition of methazolamide in human plasma and red blood cells. J. Pharm. Sci., 70 (1981) 75-81.
2. Biollaz, J., Munafo, A., Buclin, T., Gervasoni, J.-P., Magnin, J.-L., Jaquet, F. and Brunner-Ferber, F., Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide. Eur. J. Clin. Pharmacol., 47 (1995) 453-460.
3. Coleman, J.E., Chemical reactions of sulfonamides with carbonic anhydrase. Annu. Rev. Pharmacol., 15 (1975) 221-242.
4. Gibaldi M. and Perrier D., Estimation of Areas. Pharmacokinetics: Drugs and the Pharmaceutical Sciences, Marcel Dekker, New York, Vol. 15 (1982) pp. 445-449.
5. Maren, T.H., The binding of inhibitors to carbonic anhydrase in vivo: Drugs as markers for enzyme. Biochem. Pharmacol., 9 (1962) 39-48.
6. Maren, T.H., Carbonic anhydrase: Chemistry, physiology, and inhibition. Physiol. Rev., 47 (1967) 595-781.
7. Maren, T.H., Rayburn, C.S. and N.E. Liddell, N.E., Inhibition by anions of human red cell carbonic anhydrase B: Physiological and biochemical implications. Science, 191 (1976) 469-472.
8. Maren, T.H., Haywood, J.R., Chapman, S.K. and Zimmerman, T.J., The pharmacology of methazolamide in relation to the treatment of glaucoma. Invest. Ophthalmol. Visual Sci., 16 (1977) 730-742.
9. Matuszewski, B.K., Constanzer, M.L., Woolf, E.J., Au, T., Haddix, H., Determination of MK-507, a novel topically effective carbonic anhydrase inhibitor, and its de-ethylated metabolite in human whole blood, plasma, and urine by high-performance liquid chromatography. J. Chromatogr., 653 (1994) 77-85.
10. Physician's Desk Reference. 49th ed., Oradell, NJ, Medical Economics Company, 1995, pp. 1272-1273.
11. Rosenthal, H.E., A graphic method for the determination and presentation of binding parameters in a complex system. Anal. Biochem., 20 (1967) 525-532.
12. Sugrue, M.F., Waheed, A., Sly, W.S., Baldwin, J.J., Lumma, W.C. and Sondey, J.M., A study of the in vitro inhibition of human carbonic anhydrase isoenzymes I, II, and IV. Invest. Ophthalmol. Vis. Sci., 34 (Suppl.) (1993) 930.
13. Wistrand, P.J. and Baathe, P., Inhibition of carbonic anhydrase activity of whole erythrocytes. Acta Pharmacol. Toxicol (Copenhagen)., 26 (1968) 145-168.